You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
12.12.13
Ironwood Pharmaceuticals Details Strategy to Establish Leading Gastrointestinal Therapeutics Company
11.26.13
Ironwood Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference
11.21.13
Ironwood Pharmaceuticals to Host Investor Day on December 12, 2013
10.22.13
Ironwood Pharmaceuticals Provides Third Quarter 2013 Investor Update
10.08.13
Ironwood Pharmaceuticals to Host Third Quarter 2013 Investor Update Call
09.10.13
Ironwood and AstraZeneca Initiate Linaclotide Phase III Trial in China for Adults with IBS-C
09.03.13
Ironwood Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
08.21.13
Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President of Clinical Development
07.23.13
Ironwood Pharmaceuticals Provides Second Quarter 2013 Investor Update
07.09.13
Ironwood Pharmaceuticals to Host Second Quarter 2013 Investor Update Call
07.09.13
Ironwood Pharmaceuticals to Host Second Quarter 2013 Investor Update Call
06.13.13
Constella® (linaclotide), the first approved prescription therapy in a new class of treatments for adults with IBS-C, is now available in Europe
05.21.13
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
05.20.13
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock
05.14.13
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013
05.07.13
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Health Care Conference
04.23.13
Ironwood Pharmaceuticals Provides First Quarter 2013 Investor Update
04.02.13
Ironwood Pharmaceuticals to Host First Quarter 2013 Investor Update Call
03.04.13
Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors
02.25.13
Ironwood Pharmaceuticals to Present at Cowen and Company 33rd Annual Health Care Conference
02.11.13
Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D
01.15.13
Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update
01.10.13
Ironwood Pharmaceuticals to Host Fourth Quarter 2012 Investor Update Call
01.04.13
Ironwood Completes $175 Million Debt Offering
01.02.13
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
MEDIA & INVESTOR RELATIONS CONTACT
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com


Latest Tweets